Longeveron Inc. filed a Form 8-K on September 23, 2026, disclosing that its Phase 2b ELPIS II clinical trial evaluating laromestrocel in infants with hypoplastic left heart syndrome did not meet its primary efficacy endpoint.

Key Highlights

  • Trial missed primary endpoint: The ELPIS II Phase 2b trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12.
  • Least-squares mean difference: In the intent-to-treat population, the least-squares mean difference between treatment groups was -0.7 percentage points.
  • Confidence interval and p-value: The 95% confidence interval was -7.3 to 5.9, with a p-value of 0.8336.
  • Trial design: The study evaluated laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS).
  • Therapy type: Laromestrocel is described by the company as an investigational stem cell therapy.
  • Topline results announced: The press release announcing results was issued on September 16, 2026.

Longeveron Discloses ELPIS II Results for HLHS Stem Cell Therapy

According to the filing, Longeveron Inc. (NASDAQ:LGVN) reported topline results from its ELPIS II trial through an 8-K filed September 23, 2026, with the date of earliest event reported as September 16, 2026. The company describes itself as "a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions." The ELPIS II study was a Phase 2b clinical trial designed to evaluate laromestrocel, the company's investigational stem cell therapy, as an adjunct to Stage 2 palliative surgery in 40 infants diagnosed with hypoplastic left heart syndrome.

The filing states that the ELPIS II trial did not meet its primary efficacy endpoint, which was defined as change from baseline in right ventricular ejection fraction at Month 12. In the intent-to-treat population, the least-squares mean difference between treatment groups was reported as -0.7 percentage points, with a 95% confidence interval of -7.3 to 5.9 and a p-value of 0.8336, according to the disclosure. The company disclosed results via a press release, attached as Exhibit 99.1 and incorporated by reference into the filing.

The filing notes that the information included "shall not be deemed an admission as to the materiality of any information contained herein or therein." The 8-K was signed by Stephen H. Willard, identified as Chief Executive Officer of Longeveron Inc., on September 23, 2026.

What Was Disclosed

Longeveron filed an 8-K reporting that its ELPIS II Phase 2b trial of laromestrocel in 40 HLHS infants did not meet the primary endpoint of RVEF change from baseline at Month 12, with a least-squares mean difference of -0.7 percentage points and a p-value of 0.8336.